Seattle Genetics is a fast growing cancer research center in the U.S. The company has developed numerous cancer drugs such as Adcetrics. The company is planning to launch other medicinal products that will help ease the management of cancer. Adcetrics drugs are currently being tested to establish its efficacy in the management of different types of lymphomas.
The trials are part of the third phase of clinical testing which comprises trials of treating new cases of lymphoma. The experiments have already shown that Adcetrics has a positive effect in the management of lymphomas.
In 2015, the sales of Adcetrics amounted to $226 million in Canada and U.S. The sales are projected to increase to about $275 million. The company has already contracted Takeda Pharmaceuticals, a company that distributes drugs globally.
Seattle Genetics is also working on twelve other medicinal products related to the management of cancer. It is planning to release a drug branded 33A into phase three clinical trials later this year. The drug will be used to treat myeloid leukemia. Other drugs being developed are targeted at management of breast cancer and bladder cancer.
To increase their marketing strategy, Seattle Genetics is planning to recruit 100 employees in US and 20 in Switzerland. The employees will help to expand the company’s market.
Seattle Genetics boasts of a visionary leadership of Clay Siegall, its CEO and President. Clay Siegall is a renowned researcher on cancer therapies, who has been actively involved in the company’s research and drug development processes. Additionally, he has negotiated for the firm’s affiliations with leading pharmaceutical industries such as Genentech, GlaxoSmithKline, and AbbVie Inc.
Dr. Siegall graduated from University of Maryland with a Bachelor’s degree in Zoology and from George Washington University with a Ph.D. in Genetics. He has received numerous accolades for his participation in different medical research projects. In 2013, he was honored as the Alumnus of the Year for Computer, Math, and Natural Sciences at University of Maryland.
In 2012, he was honored as the Entrepreneur of the year by Pacific Northwest Ernst & Young. For this reason, he is strategically positioned to make Seattle Genetics a top player in the pharmaceutical industry.